Showing 1101-1110 of 1197 results for "".
- New from Sciton: BBLINK Goggleshttps://modernaesthetics.com/news/new-from-sciton-bblink-goggles/2473142/Sciton Inc. is launching BBLINK Goggles. These smart glasses physically blink for the user to block out strain inducing light flashes, leading to improved treatment visibility and a more pleasant experience for the practitioner. BBLINK Goggles feature proprietary technol
- As Aging Population Increases, Medical Aesthetics Market is Predicted to Growhttps://modernaesthetics.com/news/as-aging-population-increases-medical-aesthetics-market-is-predicted-to-grow/2473135/The global Medical Aesthetics Market, valued at USD 10.1 billion in 2018, is expected to reach USD 20.4 billion in 2026, growing at a CAGR of 9.0% during the forecast period, according to the latest report from All
- Kate Beckinsale Joins MRVL as the Face of its Anti-Aging Skin Care Linehttps://modernaesthetics.com/news/kate-beckinsale-joins-mrvl-as-the-face-of-its-anti-aging-skin-care-line-mrvl-skin-solutions/2473132/Kate Beckinsale is the face of MRVL Skin Solutions, an anti-aging skincare line launching this Fall. MRVL Skin Solutions is based on a novel ingredient in anti-aging: a Blue Scorpion Peptide. This peptide helps stimulate natural collagen production, fights free radicals, helps rege
- Bausch Health Pursues IPO of Solta Medicalhttps://modernaesthetics.com/news/bausch-health-pursues-ipo-of-solta-medical/2473130/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w
- Alma Introduces Women's Treatment for Alma Duohttps://modernaesthetics.com/news/alma-introduces-female-treatment-for-alma-duo/2473127/Alma is launching a new women's treatment for Alma Duo™. This new treatment protocol uses focused low-intensity extracorporeal shock wave therapy (LI-ESWT) to stimulate blood flow and help increase pleasure for women. Alma Duo, wh
- Allergan Aesthetics and Botox Cosmetic Release "See Yourself" Campaign Featuring Real Stories from Real Patientshttps://modernaesthetics.com/news/allergan-aesthetics-and-botox-cosmetic-release-see-yourself-campaign-featuring-real-stories-from-real-patients/2473110/Allergan Aesthetics is launching "See Yourself," a new campaign featuring documentary-style shorts that tell the stories of real Botox Cosmetic patients. "This campaign is just the beginning, our goal is that through authentic storytelling, people will connect with t
- Phase 3 Data: Endo’s Qwo Smooths Cellulite on the Buttockshttps://modernaesthetics.com/news/phase-3-data-endos-qwo-smooths-cellulite-on-the-buttocks/2473083/Endo’s Qwo provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women, when compared to placebo, according to Phase 3 data. "The data, from the largest cellulite studies ever conducted, provides further eviden
- Galderma Gives Back: New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://modernaesthetics.com/news/galderma-gives-back-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2473049/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- Four Years Running: Alastin Leads in Growthhttps://modernaesthetics.com/news/four-years-running-alastin-leads-in-growth/2473044/Alastin Skincare®, Inc. is the Fastest Growing Brand in the US Professional Skincare Market for the fourth year in a row. That’s according to the latest rankings from consulting and research firm Kline Group's 2020 Professional Skincare: US Market Analysis and Opportunitie
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48